BCL2L1 and leukemia: In the present study, utilizing distinct cell-surface phenotypes of different subclones identified by our framework, we recapitulated clinical responses in three patients using ex vivo drug testing, effectively targeting leukemia-regenerating cells in one patient with adverse genetics using BCL-xL inhibition.